GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (LTS:0JAV) » Definitions » Stock Based Compensation

Insmed (LTS:0JAV) Stock Based Compensation : $114.6 Mil (TTM As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Insmed Stock Based Compensation?

Insmed's Stock Based Compensation for the three months ended in Mar. 2025 was $39.3 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was $114.6 Mil.


Insmed Stock Based Compensation Historical Data

The historical data trend for Insmed's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Stock Based Compensation Chart

Insmed Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.16 46.02 57.69 74.78 96.84

Insmed Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.45 23.29 25.55 26.55 39.26

Insmed Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $114.6 Mil.


Insmed Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Insmed's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed Business Description

Industry
Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Insmed Headlines

No Headlines